FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncogynecology, and can be used to predict the progression of cervical cancer in stage IIB patients. After neoadjuvant chemotherapy, the level of CD44 expression is determined intraoperatively in the tumor tissue by immunohistochemical method. At its level above 25%, the development of disease progression is predicted within 10-27 months.
EFFECT: method makes it possible to predict the progression of cervical cancer in stage IIB patients after complex treatment, including neoadjuvant chemotherapy, by determining the level of expression in the tumor tissue of the tumor stem cell marker CD44, which is an adhesion molecule.
1 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF NEOADJUVANT TREATMENT OF PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER | 2017 |
|
RU2648642C1 |
| METHOD FOR COMBINED TREATMENT OF LOCALLY ADVANCED FORMS OF CERVICAL CANCER IIB-IIIB (T2B-T3BN0(1)M0) STAGES | 2020 |
|
RU2748135C2 |
| METHOD OF TREATING PATIENTS SUFFERING LOCALLY ADVANCED CERVICAL CANCER | 2014 |
|
RU2547569C1 |
| METHOD FOR PREVENTION OF HAEMATOGENOUS METASTASIS IN SURGICAL TREATMENT OF PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER | 2015 |
|
RU2591612C1 |
| METHOD OF TREATING PATIENTS WITH BRCA-ASSOCIATED TRIPLE-NEGATIVE LOCALLY ADVANCED BREAST CANCER | 2023 |
|
RU2814578C1 |
| METHOD OF PREDICTING UNFAVOURABLE COURSE OF LOCALLY SPREAD FORMS OF HUMAN PAPILLOMA VIRUS-ASSOCIATED CERVICAL CANCER | 2012 |
|
RU2504326C1 |
| METHOD FOR PREDICTING RECURRENCE OF SEROUS OVARIAN CARCINOMA | 2020 |
|
RU2749361C1 |
| METHOD FOR TREATMENT OF PRIMARY PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER | 2015 |
|
RU2616531C1 |
| METHOD FOR COMBINED NEOADJUVANT POLYCHEMOTHERAPY OF CERVICAL CANCER PATIENTS | 2015 |
|
RU2595855C1 |
| METHOD OF COMBINATION THERAPY APPLIED FOR LOCALLY ADVANCED CERVICAL CARCINOMA TYPES | 2006 |
|
RU2325199C2 |
